14,459 Shares in Natera, Inc. $NTRA Purchased by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,459 shares of the medical research company’s stock, valued at approximately $3,313,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the period. NewEdge Advisors LLC grew its holdings in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth grew its holdings in Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Natera during the 2nd quarter worth $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the 2nd quarter worth about $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Down 2.0%

Shares of NTRA stock opened at $218.81 on Tuesday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The firm’s fifty day simple moving average is $202.69 and its 200 day simple moving average is $215.84. The firm has a market capitalization of $31.34 billion, a P/E ratio of -134.24 and a beta of 1.56.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 482 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the completion of the sale, the chief financial officer owned 57,496 shares of the company’s stock, valued at $12,102,333.04. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 1,652 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68. Following the sale, the insider directly owned 140,643 shares of the company’s stock, valued at $28,528,026.12. This represents a 1.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 34,406 shares of company stock worth $6,984,955. 5.05% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. BTIG Research lowered their price objective on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.60.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.